KLRA — Kailera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2096997 ·
Last close
$12.20
Market Cap
$1.58B
52W High
$28.23
52W Low
$9.76
ADV30
1,032,429
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -106,336,000 | -95,665,000 | 1,082,178,000 | 106,537,000 | 51,062,000 |
| Jun 2026 | 0 | — | -121,373,000 | -111,307,000 | 1,211,416,000 | 130,301,000 | 92,952,000 |
| Mar 2026 | 0 | — | -84,660,000 | -78,865,000 | 624,756,000 | 111,826,000 | 1,056,844,000 |
| Dec 2025 | 0 | — | -67,123,000 | -62,402,000 | 692,294,000 | 160,267,000 | 1,048,752,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-325,585,000
Investing CF
$-827,818,000
Financing CF
$1,162,026,000
CapEx
$-1,645,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.83
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-654,505,000
Inventory
—
Receivables
$6,260,000
ST Investments
$794,917,000
EBIT TTM
$-379,492,000
Pretax Income TTM
$-348,239,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -158,340,000 | -148,955,000 | 692,294,000 | 1,048,752,000 | -356,458,000 | -120,210,000 |
| Dec 2024 | — | — | — | 178,445,000 | 397,217,000 | -218,772,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,211,416,000
Forward EPS
$-4.30
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $11.79 · call volume: 2 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $1.58B | $14.77 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.59B | $69.99 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.56B | $14.24 | — |
| PGEN | PRECIGEN, INC. | $1.54B | $4.29 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
News headlines (Yahoo Finance, 1h cache)
Kailera Therapeutics to Present at ObesityWeek 2026
2026-11-10 12:00 · Yahoo
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-04 21:05 · Yahoo
Kailera Therapeutics to Participate in November Investor Conferences
2026-11-03 12:15 · Yahoo
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
2026-10-01 10:45 · Yahoo
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
2026-09-30 11:44 · Yahoo
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
2026-09-30 11:00 · Yahoo
Kailera Therapeutics to Participate in September Investor Conferences
2026-09-16 11:00 · Yahoo
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
2026-09-15 04:16 · Yahoo
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
2026-08-18 14:10 · Yahoo
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
2026-08-17 13:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.